Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 641 to 650 of 2592 total matches.
Istradefylline (Nourianz) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
, or
a monoamine oxidase type B (MAO-B) inhibitor.1,2 A
subcutaneous formulation of the nonergot dopamine
agonist ...
The FDA has approved istradefylline (Nourianz —
Kyowa Kirin), an oral adenosine A2A receptor antagonist,
for use as an adjunct to carbidopa/levodopa in adults
with Parkinson's disease (PD) who experience "off"
episodes. Istradefylline is the first adenosine A2A
receptor antagonist to be approved in the US; it has
been available in Japan since 2013.
Reduction of Cardiovascular Risk with Icosapent Ethyl (Vascepa)
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
for treatment of severe hypertriglyceridemia
(≥500 mg/dL).1,2
OMEGA-3 PRODUCTS — Long-chain omega-3
PUFAs ...
Icosapent ethyl (Vascepa – Amarin), the ethyl ester
of eicosapentaenoic acid (EPA), has been approved
by the FDA for use as an adjunct to maximally
tolerated statin therapy to reduce the risk of major
adverse cardiovascular events in adults with
hypertriglyceridemia (≥150 mg/dL) who have either
established cardiovascular disease (CVD) or diabetes
and ≥2 additional risk factors for CVD. It is the only
omega-3 polyunsaturated fatty acid (PUFA) product
to be approved in the US for this indication. Icosapent
ethyl and two other omega-3 PUFA prescription
products (Lovaza, Epanova),...
Drospirenone (Slynd) - A New Progestin-Only Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
-only oral
contraceptives available in the US contain
norethindrone (Camila, and others).1 Progestin ...
The FDA has approved a progestin-only oral
contraceptive ("minipill") containing drospirenone
(Slynd – Exeltis). All other progestin-only oral
contraceptives available in the US contain
norethindrone (Camila, and others). Progestin-only oral
contraceptives are similar in efficacy to combination
oral contraceptives. They are used predominantly by
breastfeeding women and by those in whom estrogen
is poorly tolerated or contraindicated. Combination
oral contraceptives containing drospirenone and
ethinyl estradiol have been available for years.
Brolucizumab (Beovu) for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
effective and has not
been shown to improve vision.1,2
CLINICAL STUDIES — FDA approval of brolucizumab ...
Brolucizumab-dbll (Beovu — Novartis), a vascular
endothelial growth factor (VEGF) inhibitor, has been
approved by the FDA as an intravitreal injection for
treatment of neovascular (wet) age-related macular
degeneration (AMD). It is the fourth VEGF inhibitor to
be approved in the US for this indication; bevacizumab
(Avastin, and others), a VEGF inhibitor FDA-approved
for treatment of breast cancer and other malignancies,
has been used off-label for this indication for years.
In Brief: Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy
The Medical Letter on Drugs and Therapeutics • Jan 27, 2020 (Issue 1590)
transthyretin
stabilizer, in 2 different formulations (see Table 1) for
treatment of adults with transthyretin ...
The FDA has approved tafamidis, an oral transthyretin stabilizer, in 2 different formulations (see Table 1) for treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Tafamidis is the first drug to be approved in the US for this indication. Patisiran (Onpattro), a transthyretin-directed small interfering RNA, and inotersen (Tegsedi), a transthyretin-directed antisense oligonucleotide, were both recently approved for hereditary transthyretin amyloid polyneuropathy.THE DISEASE — ATTR-CM is a progressive life-threatening disease caused by destabilization of the...
Drugs for ADHD
The Medical Letter on Drugs and Therapeutics • Jan 27, 2020 (Issue 1590)
persists into adulthood.1,2 A study in
a large Danish cohort found that ADHD was associated
with higher ...
Attention-deficit/hyperactivity disorder (ADHD) is a
chronic neurodevelopmental disorder that has been
diagnosed in up to 10% of school-age children in the
US and frequently persists into adulthood. A study in
a large Danish cohort found that ADHD was associated
with higher mortality rates in children, adolescents,
and adults, mainly due to accidents. Pharmacologic
treatment of ADHD in children has been reported to
decrease the risk of substance abuse in adolescents,
and use of ADHD medications in adults has been
associated with a reduced risk of serious traffic
accidents and...
Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Jan 13, 2020 (Issue 1589)
approval for elexacaftor.
Ivacaftor is available alone (Kalydeco)1 and in
2-drug combinations ...
The FDA has approved Trikafta (Vertex), a fixed-dose
combination of the cystic fibrosis transmembrane
conductance regulator (CFTR) modulators elexacaftor,
tezacaftor, and ivacaftor, for oral treatment of cystic
fibrosis (CF) in patients ≥12 years old who have at
least one Phe508del mutation in the CFTR gene. About
90% of patients with CF have at least one copy of the
Phe508del (also called F508del) mutation. This is the
first approval for elexacaftor. Ivacaftor is available
alone (Kalydeco) and in 2-drug combinations with
tezacaftor (Symdeco) and lumacaftor...
Corticosteroids in Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • Jan 13, 2020 (Issue 1589)
of
corticosteroids as an adjunct to antimicrobials for
treatment of community-acquired pneumonia (CAP).1
CLINICAL ...
Recently updated guidelines from the American
Thoracic Society (ATS) and the Infectious Diseases
Society of America (IDSA) address the use of
corticosteroids as an adjunct to antimicrobials for
treatment of community-acquired pneumonia (CAP).
Drugs for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019 (Issue 1588)
arthritis.1 Updated guidelines for treatment
of psoriatic arthritis have recently been published.2 ...
Psoriatic arthritis is a chronic inflammatory
arthropathy associated with psoriasis. A recent review
found that about 20% of patients with psoriasis have
psoriatic arthritis. Updated guidelines for treatment
of psoriatic arthritis have recently been published.
Trifarotene (Aklief) - A New Topical Retinoid for Acne
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
by
prescription for decades. Adapalene 0.1% gel has been
available over the counter since 2016 for treatment ...
The FDA has approved trifarotene 0.005% cream
(Aklief – Galderma) for topical treatment of acne
vulgaris in patients ≥9 years old. Trifarotene is the
fourth topical retinoid to be approved in the US for
treatment of acne; tretinoin (Retin-A, and others),
adapalene (Differin, and generics), and tazarotene
(Tazorac, and others) have been available by
prescription for decades. Adapalene 0.1% gel has been
available over the counter since 2016 for treatment of
acne in patients ≥12 years old.